Pharmaceutical company Biogen Idec reported some exciting news on Tuesday December 2nd surrounding their new drug compound B11B037 for the treatment of Alzheimer's disease.

In phase 1 trials, the compound proved effective when compare to a placebo in slowing the progression of the disease and actually improving cognitive function in study patients so much so that Biogen Idec is moving aggressively to Phase Three trials immediately.

Alzheimer's disease affects more than 5 million people in the US and 35 million worldwide with that number expected to double by 2030 according to the World Health Organization to an estimate 66 million.

The initial study was not without some side affects however and Biogen Idec reports they will be working to address these issues in the next phase of clinical trials by adjusting dosage and treatment regimens.

Care providers are recognizing the need for smaller and more intimate facilities to treat those suffering with Alzheimers.

In Cincinnati, Angels Care Family Home has pioneered small house living for the care of those suffering from Alzheimers, Dementia or with Assisted Living needs by building newly constructed ADA designed homes in residential neighborhoods that provide round the clock care.

To learn more about this innovative care model, visit us at www.angelscarefh.com or contact our Operations Director Stacey Brady at 513-544-2485.